Group 1 - The core point of the article is that Jin Jing New Energy (01783) has seen a significant stock price increase due to its inclusion in the Hang Seng Composite Index, which is expected to enhance liquidity and attract more investment from mainland China [1][1][1] Group 2 - Jin Jing New Energy's stock price rose over 8% during trading, with a current increase of 6.3%, reaching HKD 8.1, and a trading volume of HKD 10.67 million [1][1][1] - The announcement of the index adjustment was made by the Hang Seng Index Company on August 22, with the changes set to take effect after market close on September 5 and officially on September 8 [1][1][1] - Analysts from UBS, CICC, and Shenwan Hongyuan have predicted that Jin Jing New Energy is likely to be included in the Hong Kong Stock Connect list, which would unlock a direct inflow channel for mainland funds [1][1][1]

Core Viewpoint - Jin Jing New Energy (01783) has seen a significant stock price increase, attributed to its inclusion in the Hang Seng Composite Index, which is expected to enhance liquidity and attract more investment from mainland China [1] Group 1: Stock Performance - The stock price of Jin Jing New Energy rose over 8% during trading, with a current increase of 6.3%, reaching HKD 8.1 [1] - The trading volume amounted to HKD 10.67 million [1] Group 2: Index Inclusion - On August 22, the Hang Seng Index Company announced its semi-annual index adjustment results, which included Jin Jing New Energy in the Hang Seng Composite Index [1] - The changes will be implemented after market close on September 5 and will take effect from September 8 [1] Group 3: Market Implications - Analysts from UBS, CICC, and Shenwan Hongyuan have predicted that Jin Jing New Energy is likely to be included in the Hong Kong Stock Connect list [1] - Inclusion in the Stock Connect is expected to unlock a direct inflow channel for mainland funds, increasing attention and favor from southern capital [1] - The anticipated passive investment from index funds will significantly enhance short-term liquidity for Jin Jing New Energy [1]

Group 1 - The core viewpoint of the article is that Jin Jing New Energy (1783.HK) experienced a significant price increase of nearly 9%, reaching HKD 8.3, following its inclusion in the Hang Seng Composite Index [1] - The Hang Seng Index Company announced on August 22 that Jin Jing New Energy will be included in the Hang Seng Composite Index, with the change effective after market close on September 5 and starting on September 8 [1] - Several institutions, including Huatai Securities, Shenwan Hongyuan, and Guozheng International, had previously anticipated that Jin Jing New Energy would be included in the Hong Kong Stock Connect investment scope [1]

Group 1 - The core point of the article is that JinJing New Energy (01783) has been included in the Hang Seng Composite Index, effective from September 8, 2025, following the announcement by the Hang Seng Index Company on August 22 [1] - Analysts suggest that once included in the Hong Kong Stock Connect, JinJing New Energy will unlock a direct channel for mainland capital inflow, potentially attracting more southbound funds and passive investments such as index funds, significantly enhancing short-term liquidity [1] - For the fiscal year 2025 (ending March 31), JinJing New Energy reported revenues of approximately HKD 870 million, representing a year-on-year increase of 92.3%. After excluding certain one-time expenses, the company achieved profitability during this period, with adjusted EBITDA recording a profit of HKD 44.76 million [1]

Group 1 - The core viewpoint of the article is that JinJing New Energy (01783) has been included in the Hang Seng Composite Index, with changes effective from September 8, 2025, following the announcement by the Hang Seng Index Company on August 22 [1] - Analysts suggest that once included in the Hong Kong Stock Connect, JinJing New Energy will unlock a direct inflow channel for mainland funds, potentially attracting more southbound capital and passive investments such as index funds, significantly enhancing short-term liquidity [1] - For the fiscal year 2025 (ending March 31), JinJing New Energy reported revenues of approximately HKD 870 million, representing a year-on-year increase of 92.3%. After excluding certain non-recurring expenses, the company achieved profitability, with adjusted EBITDA recording a profit of HKD 44.76 million [1]

Group 1 - The Hang Seng Index Company announced the results of its quarterly review, with 24 stocks including Jin Jing New Energy, CATL, Cao Cao Travel, China Foods, Heng Rui Medicine, and Chow Tai Fook being included in the Hang Seng Composite Index [1] Group 2 - The newly included companies in the index are as follows: - China Foods Limited (Code: 506) - Jiangsu Heng Rui Medicine Co., Ltd. - H Shares (Code: 1276) - Boleton Technology Co., Ltd. - H Shares (Code: 1333) - Huiju Technology Co., Ltd. (Code: 1729) - Jin Jing New Energy Holdings Limited (Code: 1783) - Country Garden Holdings Company Limited (Code: 2007) - Zhejiang Sanhua Intelligent Control Co., Ltd. - H Shares (Code: 2050) - Shanghai Konka Optical Technology Group Co., Ltd. - H Shares (Code: 2276) - Xixiangfeng Group Holdings Limited (Code: 2473) - Shanghai Auntie Baoye Co., Ltd. - H Shares (Code: 2589) - Baize Medical Group (Code: 2609) - Nanshan Aluminum International Holdings Limited (Code: 2610) - Yaojie Ankang (Nanjing) Technology Co., Ltd. - B - H Shares (Code: 2617) - MIRXES HOLDING CO. LTD. - B - F (Code: 2629) - Cao Cao Travel Co., Ltd. (Code: 2643) - Foshan Haitian Flavoring Food Co., Ltd. - H Shares (Code: 3288) - Jiangsu Zhengli New Energy Battery Technology Co., Ltd. - H Shares (Code: 3677) - Contemporary Amperex Technology Co., Limited - H Shares (Code: 3750) [2][3]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group's self-developed drug TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.20 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD for the second quarter, returning to profitability year-on-year [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinke (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - China Star Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company for the first half of the year [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group (01177) has its self-developed drug TQ05105 (JAK/ROCK inhibitor) included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.2 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD in the second quarter, returning to profitability year-on-year [1] - New World Development Company (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinkao (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - Huaxian Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Core Viewpoint - The company Jin Jing New Energy (01783) announced a proposal to split its existing issued and unissued shares with a par value of HKD 0.01 into two shares with a par value of HKD 0.005 each [1] Group 1 - The board of directors has recommended the share split to enhance liquidity and potentially attract more investors [1]

ENVISION GREENWISE HOLDINGS LIMITED 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 晉景新能控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1783） 建議股份拆細 建議股份拆細 董事會建議，將本公司股本中每股面值0.01港元之現有已發行及未發行股份拆細為兩(2) 股每股面值0.005港元之拆細股份。股份拆細將於下文「股份拆細之條件」一節所載條件 達成後生效。 股份目前於聯交所以每手1,000股股份買賣。於股份拆細生效後，拆細股份於聯交所買 賣之每手買賣單位將維持不變，每手仍為1,000股拆細股份。 一般事項 股份拆細須待股東於應屆股東週年大會上批准後，方可作實。一份載有（其中包括）股 份拆細進一步詳情及股東週年大會通告之通函將於2025年8月27日（星期三）或前後寄發 予股東。 建議股份拆細 董事會建議，將本公司股本中每股面值0.01港元之現有已發行及未發行股份拆細為兩(2) 股每股面值0.005港元 ...